Exploring Biomarkers for Depression

CompletedOBSERVATIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 14, 2017

Study Completion Date

October 14, 2017

Conditions
Major Depressive Disorder
Interventions
DRUG

Escitalopram

An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.

OTHER

Healthy Control

No Treatment

Trial Locations (1)

02114

Depression Clinical and Research Program, MGH, Boston

All Listed Sponsors
collaborator

Massachusetts General Hospital

OTHER

collaborator

Martinos Center for Biomedical Imaging

OTHER

collaborator

Massachusetts Institute of Technology

OTHER

lead

Wyss Institute at Harvard University

OTHER

NCT01424111 - Exploring Biomarkers for Depression | Biotech Hunter | Biotech Hunter